Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
CordenPharma Colorado Completes Highly Potent API Lab Expansion
Capable of handling highly potent compounds with an OEL as low as 1ng/m3.Contract Pharma Staff 10.19.20
-
Aseptic Processing | Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
ILC Dover Acquires Solo Containment
UK-based provider of products used in pharmaceutical and biopharmaceutical manufacturing.Contract Pharma Staff 09.14.20
-
Biologics, Proteins, Vaccines | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.Contract Pharma Staff 09.09.20
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Seqens Opens New HPAPI Unit
Will produce highly active ingredients at its Villeneuve-La-Garenne site.Contract Pharma Staff 09.03.20
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Catalent to Expand Argentinian Site in Buenos Aires
Adding 11,000 sq.-ft. of production space segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.Contract Pharma Staff 08.04.20
-
APIs | Cytotoxics and High Potency Manufacturing
The CDMO Landscape: Controlled Substance APIs
Meeting the growing demand for the development and manufacture of controlled substance APIs.Mike Gibson, R&D Director, Sterling Pharma Solutions 06.04.20
-
Cytotoxics and High Potency Manufacturing
Highly Potent and Highly Specialized
CDMO model meets the HPAPI market demand.Youchu Wang, VP Process R&D, WuXi STA 06.04.20
-
Cytotoxics and High Potency Manufacturing
HPAPI Drug Manufacturing Trends
Managing accelerated timelines in manufacturing high-potency drugs.Maurits Janssen, Head of Commercial Development, Lonza Pharma & Biotech 05.05.20
-
Cytotoxics and High Potency Manufacturing | Fill/Finish | Information Technology
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Piramal to Expand Aurora Facility
To add 10,500 sq.-ft. state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients01.28.20
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
HPAPI Market Trends: PCI Expands Capabilities
Michael Ellingson of PCI discusses market demand for specialty drug product capabilities and the Rockford, IL expansionOnline Exclusives Kristin Brooks, Cotract Pharma 01.10.20
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities
Flamma Arrives in the U.S.
Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.Tim Wright, Editor, Contract Pharma 10.15.19
-
Cytotoxics and High Potency Manufacturing
-
Cytotoxics and High Potency Manufacturing
High Containment & Cost Savings with Single Use Isolator Technology
The trend towards HPAPIs is driving the need for innovative containment systems.Scott Patterson, Vice President Commercial Sales, ILC Dover 09.16.19
-
Cytotoxics and High Potency Manufacturing
Handling & Assessing HPAPIs
As oncology pipelines grow, so too is the demand for highly potent materials, which require careful handling and containment.Jason Korbel, Technical Services Manager, Cambrex Charles City 09.16.19
-
Cytotoxics and High Potency Manufacturing
API to ADC: A Journey Through High Potency
This class of compounds represents a major advance in oncology research and treatment application.Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Piramal Invests $10 million in Riverview Expansion
Expands High Potency API Capability to serve the growing ADC market06.21.19
-
Bio News | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Lonza to Expand HPAPI Development and Manufacturing Capacity
Will develop new facilities at Visp site; enters long term mfg. agreement with AstraZeneca06.14.19
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Cambrex Completes Highly Potent API Mfg. Site
Investment in Charles City, IA site totaled $24 million04.11.19
